Ticker

Analyst Price Targets — FLGT

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
August 4, 2026 10:51 amDavid WestenbergPiper Sandler$19.00$17.61TheFly Fulgent Genetics price target raised to $19 from $15 at Piper Sandler
May 5, 2026 10:52 amPiper Sandler$15.00$15.12TheFly Fulgent Genetics price target lowered to $15 from $30 at Piper Sandler
November 14, 2025 9:21 amAndrew CooperRaymond James$36.00$29.59StreetInsider Fulgent Genetics (FLGT) PT Raised to $36 at Raymond James
August 5, 2025 9:29 amUBS$30.00$20.78TheFly Fulgent Genetics upgraded to Buy from Neutral at UBS
August 4, 2025 10:44 amPiper Sandler$21.00$18.36TheFly Fulgent Genetics price target lowered to $21 from $23 at Piper Sandler
May 5, 2025 12:09 pmAndrew CooperRaymond James$25.00$19.56TheFly Fulgent Genetics price target raised to $25 from $24 at Raymond James
December 8, 2022 5:14 amPiper Sandler$40.00$37.07Benzinga Piper Sandler Downgrades Fulgent Genetics to Neutral, Lowers Price Target to $40
November 18, 2022 7:29 amRaymond James$45.00$35.89Benzinga Raymond James Initiates Coverage On Fulgent Genetics with Outperform Rating, Announces Price Target of $45
November 14, 2022 7:30 amCredit Suisse$50.00$39.24Benzinga Credit Suisse Maintains Outperform on Fulgent Genetics, Lowers Price Target to $50
May 15, 2022 9:14 pmDavid WestenbergPiper Sandler$70.00$54.45TheFly Fulgent Genetics price target lowered to $70 from $85 at Piper Sandler

Latest News for FLGT

Hsbc Holdings PLC Purchases New Position in Fulgent Genetics, Inc. $FLGT

Hsbc Holdings PLC purchased a new stake in shares of Fulgent Genetics, Inc. (NASDAQ: FLGT) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 45,048 shares of the company's stock, valued at approximately $915,000. Hsbc Holdings PLC owned about 0.16% of Fulgent Genetics

Defense World • Sep 2, 2026
Fulgent Genetics Q2 Earnings Call Highlights

Fulgent Genetics NASDAQ: FLGT reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower collection rates during a transition to a new billing and revenue-cycle-management system.

MarketBeat • Jul 30, 2026
Fulgent Reports Second Quarter 2026 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Results: Revenue of $85.4 million GAAP loss of $29.5 million, or $(1.05) per share Non-GAAP loss…

Business Wire • Jul 30, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for FLGT.

No House trades found for FLGT.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top